The global pulmonary arterial hypertension market size is anticipated to reach USD 11.0 billion by 2030. The market is expected to expand at a lucrative CAGR of 5.2% from 2022 to 2030. The key factors driving the market growth include the increasing prevalence of pulmonary arterial hypertension, drug development and technological advancements, product approvals, and initiatives by key companies.
The COVID-19 pandemic had a notable impact on the market. The pandemic created uncertain market conditions and lead to dampened growth. Other impacts of the pandemic include operational challenges, supply chain bottlenecks, challenges in conducting clinical trials, among others. Market players also reported a reduction in new patient starts and new patient prescriptions during 2020.
For instance, the sales of Remodulin, Tyvaso, and Orenitram were affected by the reduction in new patient starts, during the second quarter of 2020. However, the new patient starts gradually recovered to pre-pandemic numbers during the second half of 2020. Market players responded to the COVID-19 pandemic by deploying various initiatives. These included maintaining a strong financial position, maintaining ample supply of products, deploying measures to facilitate uninterrupted distribution to patients, and R&D activities among others. Overall sales of PAH drugs, however, were largely unaffected by the pandemic as market players ensured ample supply during the pandemic.
Supportive product approvals by regulatory agencies such as an extended indication of use, first generics approval, approval of drug delivery devices, etc. are estimated to fuel the market growth in the near future. In March 2021, United Therapeutics’ Tyvaso received FDA clearance for use in patients with pulmonary hypertension associated with interstitial lung disease. In February 2021, the company launched- the Remunity Pump in the U.S.- a new subcutaneous delivery system for its key treprostinil product Remodulin.
The COVID-19 pandemic had a notable impact on the market. The pandemic created uncertain market conditions and lead to dampened growth. Other impacts of the pandemic include operational challenges, supply chain bottlenecks, challenges in conducting clinical trials, among others. Market players also reported a reduction in new patient starts and new patient prescriptions during 2020.
For instance, the sales of Remodulin, Tyvaso, and Orenitram were affected by the reduction in new patient starts, during the second quarter of 2020. However, the new patient starts gradually recovered to pre-pandemic numbers during the second half of 2020. Market players responded to the COVID-19 pandemic by deploying various initiatives. These included maintaining a strong financial position, maintaining ample supply of products, deploying measures to facilitate uninterrupted distribution to patients, and R&D activities among others. Overall sales of PAH drugs, however, were largely unaffected by the pandemic as market players ensured ample supply during the pandemic.
Supportive product approvals by regulatory agencies such as an extended indication of use, first generics approval, approval of drug delivery devices, etc. are estimated to fuel the market growth in the near future. In March 2021, United Therapeutics’ Tyvaso received FDA clearance for use in patients with pulmonary hypertension associated with interstitial lung disease. In February 2021, the company launched- the Remunity Pump in the U.S.- a new subcutaneous delivery system for its key treprostinil product Remodulin.
Pulmonary Arterial Hypertension Market Report Highlights
- The market was valued at USD 7.0 billion in 2021 and is expected to expand at a CAGR of 5.2% during the forecast period
- The prostacyclin and prostacyclin analogs segment held the largest share of the market by drug class in 2021. The sales of these drugs are anticipated to grow sharply in the future, primarily due to the growth expected in oral, intravenous, subcutaneous, and inhalational prostacyclin agents
- The branded drugs segment dominated the market in 2021 while the generics segment is anticipated to grow at the fastest rate from 2022 to 2030
- In 2021, the oral segment accounted for the largest revenue share of the market by route of administration owing to the greater availability of PAH formulations as oral products such as tablets, powders, and suspension
- North America dominated the market in 2021 owing to a high adoption rate and supportive infrastructure for the development and distribution of high-quality therapies. Also, the availability of reimbursement on PAH therapies supported market growth
- Asia Pacific is anticipated to witness the fastest CAGR over the forecast period due to its huge population base, rapid economic developments, and improving healthcare infrastructure
Table of Contents
Chapter 1 Methodology and Scope1.1 Market Segmentation and Scope
1.1.1 Segment scope
1.1.2 Regional scope
1.1.3 Estimates and forecast timeline
1.2 Research Methodology
1.3 Information procurement
1.3.1 Purchased database
1.3.2 internal database
1.3.3 Secondary sources
1.3.4 Primary research
1.3.5 Details of primary research
1.4 Information or Data Analysis
1.4.1 Data analysis models
1.5 Market Formulation & Validation
1.6 Model Details
1.7 List of Secondary Sources
1.8 Objectives
Chapter 2 Executive Summary
2.1 Pulmonary Arterial Hypertension Market Summary
Chapter 3 Pulmonary Arterial Hypertension Market Variables, Trends & Scope
3.1 Market Lineage Outlook
3.1.1 Parent Market
3.1.2 Ancillary Market
3.2 Penetration & Growth Prospect Mapping
3.3 Product Pipeline Analysis, By Stage
3.4 User Perspective Analysis
3.4.1 Consumer Behavior Analysis
3.4.2 Market Influencer Analysis
3.5 Pah Branded Market Sales By Drug Class 2017 - 2030 (In Million Units)
3.6 List Of Generic Drugs
3.7 Regulatory Framework
3.7.1 Reimbursement Framework
3.7.2 Standards & Compliances
3.8 Market Variable Analysis
3.8.1 Market Driver Analysis
3.8.2 Market Restraint Analysis
3.8.3 Industry Challenges
3.9 Pulmonary Arterial Hypertension Market: Analysis Tools
3.9.1 Porter’s Five Forces Analysis
3.9.1.1 Supplier Power
3.9.1.2 Buyer Power
3.9.1.3 Substitution Threat
3.9.1.4 Threat From New Entrant
3.9.1.5 Competitive Rivalry
3.9.2 Pestel Analysis
3.10 Major Deals & Strategic Alliances Analysis
3.10.1.1 Product Development
3.10.1.2 Mergers & Acquisitions
3.10.1.3 Product Promotion Strategies
3.11 Market Entry Strategies
3.12 Disease Prevalence Analysis
3.13. Patent Expiry
3.14. Pricing Analysis
Chapter 4 COVID - 19 Impact Analysis
4.1 COVID - 19 Prevalence Analysis
4.2. Current Impact & Future Scenario
4.3. Impact on Market Players
Chapter 5 Pulmonary Arterial Hypertension Market: Segment Analysis, By Drug Class, 2017 - 2030 (USD Million)
5.1 Drug Class Market Share Analysis, 2021 & 2030
5.2 Pulmonary Arterial Hypertension market, by Drug Class, 2017 to 2030
5.3 Endothelin Receptor Antagonists (ERAs)
5.3.1 Endothelin Receptor Antagonists (ERAs) market, 2017 - 2030 (USD Million)
5.4 PDE - 5 Inhibitors
5.4.1 PDE - 5 Inhibitors market, 2017 - 2030 (USD Million)
5.5 Prostacyclin and Prostacyclin Analogs
5.5.1 Prostacyclin and Prostacyclin Analogs market, 2017 - 2030 (USD Million)
5.6 SGC Stimulators
5.6.1 SGC Stimulators market, 2017 - 2030 (USD Million)
Chapter 6 Pulmonary Arterial Hypertension Market: Segment Analysis, By Type, 2017 - 2030 (USD Million)
6.1 Type Market Share Analysis, 2021 & 2030
6.2 Pulmonary Arterial Hypertension market, by Type, 2017 to 2030
6.3 Branded
6.3.1 Branded market, 2017 - 2030 (USD Million)
6.4 Generics
6.4.1 Generics market, 2017 - 2030 (USD Million)
Chapter 7 Pulmonary Arterial Hypertension Market: Segment Analysis, By Route of Administration, 2017 - 2030 (USD Million)
7.1 Route of Administration Market Share Analysis, 2021 & 2030
7.2 Pulmonary Arterial Hypertension Market, by Route of Administration, 2017 to 2030
7.3 Oral
7.3.1 Oral market, 2017 - 2030 (USD Million)
7.4 Intravenous/ subcutaneous
7.4.1 Intravenous/ subcutaneous market, 2017 - 2030 (USD Million)
7.5 Inhalational
7.5.1 Inhalational market, 2017 - 2030 (USD Million)
Chapter 8 Pulmonary Arterial Hypertension Market: Regional Market Analysis 2017 - 2030 (USD Million)
8.1 Definition & Scope
8.2 Regional Movement Analysis, 2021 & 2030
8.3 Regional Market Snapshot
8.4 North America
8.4.1 North America Pulmonary Arterial Hypertension Market, 2017 - 2030 (USD Million)
8.4.2. U.S.
8.4.2.1 U.S. Pulmonary Arterial Hypertension Market, 2017 - 2030 (USD Million)
8.4.3 Canada
8.4.3.1 Canada Pulmonary Arterial Hypertension Market, 2017 - 2030 (USD Million)
8.5 Europe
8.5.1 Europe Pulmonary Arterial Hypertension Market, 2017 - 2030 (USD Million)
8.5.2 U.K.
8.5.2.1 U.K. Pulmonary Arterial Hypertension Market, 2017 - 2030 (USD Million)
8.5.3 Germany
8.5.3.1 Germany Pulmonary Arterial Hypertension Market, 2017 - 2030 (USD Million)
8.5.4 France
8.5.4.1 France Pulmonary Arterial Hypertension Market, 2017 - 2030 (USD Million)
8.5.5 Italy
8.5.5.1 Italy Pulmonary Arterial Hypertension Market, 2017 - 2030 (USD Million)
8.5.6 Spain
8.5.6.1 Spain Pulmonary Arterial Hypertension Market, 2017 - 2030 (USD Million)
8.6 Asia Pacific
8.6.1 Asia Pacific Pulmonary Arterial Hypertension market, 2017 - 2030 (USD Million)
8.6.2 Japan
8.6.2.1 Japan Pulmonary Arterial Hypertension Market, 2017 - 2030 (USD Million)
8.6.3 China
8.6.3.1 China Pulmonary Arterial Hypertension Market, 2017 - 2030 (USD Million)
8.6.4 India
8.6.4.1 India Pulmonary Arterial Hypertension Market, 2017 - 2030 (USD Million)
8.6.5 Australia
8.6.5.1 Australia Pulmonary Arterial Hypertension Market, 2017 - 2030 (USD Million)
8.6.6 South Korea
8.6.6.1 South Korea Pulmonary Arterial Hypertension Market, 2017 - 2030 (USD Million)
8.7 Latin America
8.7.1 Latin America Pulmonary Arterial Hypertension Market, 2017 - 2030 (USD Million)
8.7.2 Brazil
8.7.2.1 Brazil Pulmonary Arterial Hypertension Market, 2017 - 2030 (USD Million)
8.7.3 Mexico
8.7.3.1 Mexico Pulmonary Arterial Hypertension Market, 2017 - 2030 (USD Million)
8.7.4 Argentina
8.7.4.1 Argentina Pulmonary Arterial Hypertension Market, 2017 - 2030 (USD Million)
8.8 MEA
8.8.1 MEA Pulmonary Arterial Hypertension Market, 2017 - 2030 (USD Million)
8.8.2 South Africa
8.8.2.1 South Africa Pulmonary Arterial Hypertension Market, 2017 - 2030 (USD Million)
8.8.3 Saudi Arabia
8.8.3.1 Saudi Arabia Pulmonary Arterial Hypertension Market, 2017 - 2030 (USD Million)
8.8.4 UAE
8.8.4.1 UAE Pulmonary Arterial Hypertension Market, 2017 - 2030 (USD Million)
Chapter 9 Pulmonary Arterial Hypertension Market - Competitive Analysis
9.1 Market Participant Categorization
9.1.1. Company Market Position Analysis
9.1.2. Synergy Analysis: Major Deals & Strategic Alliances
9.1.3. Market Leaders
9.1.4. Innovators
9.2. List of Companies
Chapter 10 Pulmonary Arterial Hypertension Market - Company Profiles
10.1 United Therapeutics Corporation
10.1.1 Company overview
10.1.2 Financial performance
10.1.3 Type benchmarking
10.1.4 Strategic initiatives
10.2 Bayer
10.2.1 Company overview
10.2.2 Financial performance
10.2.3 Type benchmarking
10.2.4 Strategic initiatives
10.3 Gilead Sciences, Inc.
10.3.1 Company overview
10.3.2 Financial performance
10.3.3 Type benchmarking
10.3.4 Strategic initiatives
10.4 Johnson & Johnson
10.4.1 Company overview
10.4.2 Financial performance
10.4.3 Type benchmarking
10.4.4 Strategic initiatives
10.5 Viatris Inc.
10.5.1 Company overview
10.5.2 Financial performance
10.5.3 Type benchmarking
10.5.4 Strategic initiatives
10.6 GlaxoSmithKline
10.6.1 Company overview
10.6.2 Financial performance
10.6.3 Type benchmarking
10.6.4 Strategic initiatives
10.7 Sandoz Inc. (Novartis)
10.7.1 Company overview
10.7.2 Financial performance
10.7.3 Type benchmarking
10.7.4 Strategic initiatives
10.8 Lupin Pharmaceuticals, Inc.
10.8.1 Company overview
10.8.2 Financial performance
10.8.3 Type benchmarking
10.8.4 Strategic initiatives
10.9 Sun Pharmaceutical Industries, Inc.
10.9.1 Company overview
10.9.2 Financial performance
10.9.3 Type benchmarking
10.9.4 Strategic initiatives
10.10 Teva Pharmaceutical Industries Ltd.
10.10.1 Company overview
10.10.2 Financial performance
10.10.3 Type benchmarking
10.10.4 Strategic initiatives
List of Tables
Table 1 List of secondary sources
Table 2 Average selling prices for approved PAH agents in the U.S. (2020)
Table 3 North America Pulmonary Arterial Hypertension market, by country, 2017 - 2030 (USD Million)
Table 4 North America Pulmonary Arterial Hypertension market, by Type, 2017 - 2030 (USD Million)
Table 5 North America Pulmonary Arterial Hypertension market, by Route of Administration, 2017 - 2030 (USD Million)
Table 6 North America Pulmonary Arterial Hypertension market, by Drug Class, 2017 - 2030 (USD Million)
Table 7 U.S. Pulmonary Arterial Hypertension market, by Type, 2017 - 2030 (USD Million)
Table 8 U.S. Pulmonary Arterial Hypertension market, by Route of Administration, 2017 - 2030 (USD Million)
Table 9 U.S. Pulmonary Arterial Hypertension market, by Drug Class, 2017 - 2030 (USD Million)
Table 10 Canada Pulmonary Arterial Hypertension market, by Type, 2017 - 2030 (USD Million)
Table 11 Canada Pulmonary Arterial Hypertension market, by Route of Administration, 2017 - 2030 (USD Million)
Table 12 Canada Pulmonary Arterial Hypertension market, by Drug Class, 2017 - 2030 (USD Million)
Table 13 Europe Pulmonary Arterial Hypertension market, by country, 2017 - 2030 (USD Million)
Table 14 Europe Pulmonary Arterial Hypertension market, by Type, 2017 - 2030 (USD Million)
Table 15 Europe Pulmonary Arterial Hypertension market, by Route of Administration, 2017 - 2030 (USD Million)
Table 16 Europe Pulmonary Arterial Hypertension market, by Drug Class, 2017 - 2030 (USD Million)
Table 17 U.K. Pulmonary Arterial Hypertension market, by Type, 2017 - 2030 (USD Million)
Table 18 U.K. Pulmonary Arterial Hypertension market, by Route of Administration, 2017 - 2030 (USD Million)
Table 19 U.K. Pulmonary Arterial Hypertension market, by Drug Class, 2017 - 2030 (USD Million)
Table 20 Germany Pulmonary Arterial Hypertension market, by Type, 2017 - 2030 (USD Million)
Table 21 Germany Pulmonary Arterial Hypertension market, by Route of Administration, 2017 - 2030 (USD Million)
Table 22 Germany Pulmonary Arterial Hypertension market, by Drug Class, 2017 - 2030 (USD Million)
Table 23 France Pulmonary Arterial Hypertension market, by Type, 2017 - 2030 (USD Million)
Table 24 France Pulmonary Arterial Hypertension market, by Route of Administration, 2017 - 2030 (USD Million)
Table 25 France Pulmonary Arterial Hypertension market, by Drug Class, 2017 - 2030 (USD Million)
Table 26 Italy Pulmonary Arterial Hypertension market, by Type, 2017 - 2030 (USD Million)
Table 27 Italy Pulmonary Arterial Hypertension market, by Route of Administration, 2017 - 2030 (USD Million)
Table 28 Italy Pulmonary Arterial Hypertension market, by Drug Class, 2017 - 2030 (USD Million)
Table 29 Spain Pulmonary Arterial Hypertension market, by Type, 2017 - 2030 (USD Million)
Table 30 Spain Pulmonary Arterial Hypertension market, by Route of Administration, 2017 - 2030 (USD Million)
Table 31 Spain Pulmonary Arterial Hypertension market, by Drug Class, 2017 - 2030 (USD Million)
Table 32 Asia Pacific Pulmonary Arterial Hypertension market, by country, 2017 - 2030 (USD Million)
Table 33 Asia Pacific Pulmonary Arterial Hypertension market, by Type, 2017 - 2030 (USD Million)
Table 34 Asia Pacific Pulmonary Arterial Hypertension market, by Route of Administration, 2017 - 2030 (USD Million)
Table 35 Asia Pacific Pulmonary Arterial Hypertension market, by Drug Class, 2017 - 2030 (USD Million)
Table 36 China Pulmonary Arterial Hypertension market, by Type, 2017 - 2030 (USD Million)
Table 37 China Pulmonary Arterial Hypertension market, by Route of Administration, 2017 - 2030 (USD Million)
Table 38 China Pulmonary Arterial Hypertension market, by Drug Class, 2017 - 2030 (USD Million)
Table 39 Japan Pulmonary Arterial Hypertension market, by Type, 2017 - 2030 (USD Million)
Table 40 Japan Pulmonary Arterial Hypertension market, by Route of Administration, 2017 - 2030 (USD Million)
Table 41 Japan Pulmonary Arterial Hypertension market, by Drug Class, 2017 - 2030 (USD Million)
Table 42 India Pulmonary Arterial Hypertension market, by Type, 2017 - 2030 (USD Million)
Table 43 India Pulmonary Arterial Hypertension market, by Route of Administration, 2017 - 2030 (USD Million)
Table 44 India Pulmonary Arterial Hypertension market, by Drug Class, 2017 - 2030 (USD Million)
Table 45 Australia Pulmonary Arterial Hypertension market, by Type, 2017 - 2030 (USD Million)
Table 46 Australia Pulmonary Arterial Hypertension market, by Route of Administration, 2017 - 2030 (USD Million)
Table 47 Australia Pulmonary Arterial Hypertension market, by Drug Class, 2017 - 2030 (USD Million)
Table 48 South Korea Pulmonary Arterial Hypertension market, by Type, 2017 - 2030 (USD Million)
Table 49 South Korea Pulmonary Arterial Hypertension market, by Route of Administration, 2017 - 2030 (USD Million)
Table 50 South Korea Pulmonary Arterial Hypertension market, by Drug Class, 2017 - 2030 (USD Million)
Table 51 Latin America Pulmonary Arterial Hypertension market, by country, 2017 - 2030 (USD Million)
Table 52 Latin America Pulmonary Arterial Hypertension market, by Type, 2017 - 2030 (USD Million)
Table 53 Latin America Pulmonary Arterial Hypertension market, by Route of Administration, 2017 - 2030 (USD Million)
Table 54 Latin America Pulmonary Arterial Hypertension market, by Drug Class, 2017 - 2030 (USD Million)
Table 55 Brazil Pulmonary Arterial Hypertension market, by Type, 2017 - 2030 (USD Million)
Table 56 Brazil Pulmonary Arterial Hypertension market, by Route of Administration, 2017 - 2030 (USD Million)
Table 57 Brazil Pulmonary Arterial Hypertension market, by Drug Class, 2017 - 2030 (USD Million)
Table 58 Mexico Pulmonary Arterial Hypertension market, by Type, 2017 - 2030 (USD Million)
Table 59 Mexico Pulmonary Arterial Hypertension market, by Route of Administration, 2017 - 2030 (USD Million)
Table 60 Mexico Pulmonary Arterial Hypertension market, by Drug Class, 2017 - 2030 (USD Million)
Table 61 Argentina Pulmonary Arterial Hypertension market, by Type, 2017 - 2030 (USD Million)
Table 62 Argentina Pulmonary Arterial Hypertension market, by Route of Administration, 2017 - 2030 (USD Million)
Table 63 Argentina Pulmonary Arterial Hypertension market, by Drug Class, 2017 - 2030 (USD Million)
Table 64 MEA Pulmonary Arterial Hypertension market, by country, 2017 - 2030 (USD Million)
Table 65 MEA Pulmonary Arterial Hypertension market, by Type, 2017 - 2030 (USD Million)
Table 66 MEA Pulmonary Arterial Hypertension market, by Route of Administration, 2017 - 2030 (USD Million)
Table 67 MEA Pulmonary Arterial Hypertension market, by Drug Class, 2017 - 2030 (USD Million)
Table 68 South Africa Pulmonary Arterial Hypertension market, by Type, 2017 - 2030 (USD Million)
Table 69 South Africa Pulmonary Arterial Hypertension market, by Route of Administration, 2017 - 2030 (USD Million)
Table 70 South Africa Pulmonary Arterial Hypertension market, by Drug Class, 2017 - 2030 (USD Million)
Table 71 Saudi Arabia Pulmonary Arterial Hypertension market, by Type, 2017 - 2030 (USD Million)
Table 72 Saudi Arabia Pulmonary Arterial Hypertension market, by Route of Administration, 2017 - 2030 (USD Million)
Table 73 Saudi Arabia Pulmonary Arterial Hypertension market, by Drug Class, 2017 - 2030 (USD Million)
Table 74 UAE Pulmonary Arterial Hypertension market, by Type, 2017 - 2030 (USD Million)
Table 75 UAE Pulmonary Arterial Hypertension market, by Route of Administration, 2017 - 2030 (USD Million)
Table 76 UAE Pulmonary Arterial Hypertension market, by Drug Class, 2017 - 2030 (USD Million)
Table 77 Global Pulmonary Arterial Hypertension market, by region, 2017 - 2030 (USD Million)
Table 78 Global Pulmonary Arterial Hypertension market, by Type, 2017 - 2030 (USD Million)
Table 79 Global Pulmonary Arterial Hypertension market, by Route of Administration, 2017 - 2030 (USD Million)
Table 80 Global Pulmonary Arterial Hypertension market, by Drug Class, 2017 - 2030 (USD Million)
Table 81 Global Pulmonary Arterial Hypertension (PAH) market, by Drug Class, 2017 - 2030 (Million Units)
Table 82 North America Pulmonary Arterial Hypertension (PAH) market, by Drug Class, 2017 - 2030 (Million Units)
Table 83 Europe Pulmonary Arterial Hypertension (PAH) market, by Drug Class, 2017 - 2030 (Million Units)
Table 84 Asia Pacific Pulmonary Arterial Hypertension (PAH) market, by Drug Class, 2017 - 2030 (Million Units)
Table 85 Latin America Pulmonary Arterial Hypertension (PAH) market, by Drug Class, 2017 - 2030 (Million Units)
Table 86 MEA Pulmonary Arterial Hypertension (PAH) market, by Drug Class, 2017 - 2030 (Million Units)
Table 87 Global Pulmonary Arterial Hypertension (PAH) market, by Drug Class, 2017 - 2030 (ASP in USD)
Table 88 Summary of pipeline analysis for Early Phase I & Phase I PAH agents
Table 89 Summary of pipeline analysis for Phase II PAH agents
Table 90 Summary of pipeline analysis for Phase III PAH agents
Table 91 Summary of pipeline analysis for Phase IV PAH agentsList of Figures
Fig. 1 PAH market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Primary research pattern
Fig. 6 Market research approaches
Fig. 7 Value-chain-based sizing & forecasting
Fig. 8 QFD modeling for market share assessment
Fig. 9 Market formulation & validation
Fig. 10 Commodity flow analysis
Fig. 11 Market snapshot, 2021 (USD Million)
Fig. 12 Patent term expiry of the key PAH brands
Fig. 13 Ancillary market analysis
Fig. 14 Penetration & growth prospect mapping
Fig. 15 Consumer behavior analysis
Fig. 16 Market influencer analysis
Fig. 17 Market variables
Fig. 18 Market driver analysis
Fig. 19 Global prevalence of PAH
Fig. 20 Global geriatric population
Fig. 21 Market restraint analysis
Fig. 22 Market participant categorization
Fig. 23 Company market position analysis: Heat map analysis
Fig. 24 Strategy mapping
Fig. 25 Market entry strategies
Fig. 26 PAH market: Drug class dashboard
Fig. 27 PAH market: Drug class movement analysis
Fig. 28 Prostacyclin pathway
Fig. 29 Prostacyclin and prostacyclin analogs market, 2017 - 2030 (USD Million)
Fig. 30 Nitric oxide pathway
Fig. 31 SGC stimulators market, 2017 - 2030 (USD Million)
Fig. 32 Endothelial pathway
Fig. 33 ERA market, 2017 - 2030 (USD Million)
Fig. 34 PDE-5 market, 2017 - 2030 (USD Million)
Fig. 35 PAH market, by regions, 2017 - 2030 (USD Million)
Fig. 36 Regional marketplace: Key takeaways
Fig. 37 Regional outlook, 2021 & 2030
Fig. 38 North America PAH market, 2017 - 2030(USD Million)
Fig. 39 U.S. PAH market, 2017 - 2030(USD Million)
Fig. 40 Canada PAH market, 2017 - 2030(USD Million)
Fig. 41 Europe PAH market, 2017 - 2030(USD Million)
Fig. 42 U.K. PAH market, 2017 - 2030(USD Million)
Fig. 43 Germany PAH market, 2017 - 2030(USD Million)
Fig. 44 France PAH market, 2017 - 2030 (USD Million)
Fig. 45 Italy PAH market, 2017 - 2030 (USD Million)
Fig. 46 Spain PAH market, 2017- 2030 (USD Million)
Fig. 47 Asia Pacific PAH market, 2017 - 2030 (USD Million)
Fig. 48 Japan PAH market, 2017 - 2030 (USD Million)
Fig. 49 China PAH market, 2017 - 2030 (USD Million)
Fig. 50 India PAH market, 2017 - 2030 (USD Million)
Fig. 51 South Korea PAH market, 2017- 2030(USD Million)
Fig. 52 Australia PAH market, 2017 - 2030 (USD Million)
Fig. 53 Latin America PAH market, 2017 - 2030 (USD Million)
Fig. 54 Brazil PAH market, 2017 - 2086 (USD Million)
Fig. 55 Mexico PAH market, 2017 - 2030 (USD Million)
Fig. 56 Argentina PAH market, 2017 - 2030 (USD Million)
Fig. 57 MEA PAH market, 2017 - 2030 (USD Million)
Fig. 58 South Africa PAH market, 2017 - 2030 (USD Million)
Fig. 59 Saudi Arabia PAH market, 2017 - 2030 (USD Million)
Fig. 60 UAE PAH market, 2017 - 2030 (USD Million)
Fig. 61 COVID-19 disease prevalence
Fig. 62 Pulmonary Arterial Hypertension market: Type movement analysis, 2021 & 2030
Fig. 63 Pulmonary Arterial Hypertension market Type outlook: Key takeaways
Fig. 64 Branded market, 2017 - 2030 (USD Million)
Fig. 65 Generics market, 2017 - 2030 (USD Million)
Fig. 66 Pulmonary Arterial Hypertension market: Route of Administration movement analysis 2021 & 2030
Fig. 67 Pulmonary Arterial Hypertension market Route of Administration outlook: Key takeaways
Fig. 68 Oral market, 2017 - 2030 (USD Million)
Fig. 69 Intravenous/ subcutaneous market, 2017 - 2030 (USD Million)
Fig. 70 Inhalational market, 2017 - 2030 (USD Million)
Companies Mentioned
- United Therapeutics Corporation
- Bayer
- Gilead Sciences, Inc.
- Johnson & Johnson
- Viatris Inc.
- GlaxoSmithKline
- Sandoz Inc. (Novartis)
- Lupin Pharmaceuticals, Inc.
- Sun Pharmaceutical Industries, Inc.
- Teva Pharmaceutical Industries Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 150 |
| Published | January 2022 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value ( USD | $ 7.34 Billion |
| Forecasted Market Value ( USD | $ 11 Billion |
| Compound Annual Growth Rate | 5.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
